February 04, 2022
In this exclusive video interview, Michal Elovitz, MD, chief medical advisor at Mirvie, discusses the latest data from the RNA testing platform in predicting preterm birth at the SMFM 42nd Annual Pregnancy Meeting.
February 02, 2022
Medication can now be used as few as 6 times a year for virologically suppressed adults living with the disease without prior treatments not working or resistance to cabotegravir or rilpivirine.
February 01, 2022
Sarah Lee, MD, MBA, discusses the use of checkpoint inhibitors in endometrial cancer, research regarding the association between MSI-H, dMMR, and TMB-H disease, and the importance of broad molecular testing to ensure all eligible patients are appropriately matched to immunotherapeutic options.
January 31, 2022
The drug is used to treat bacterial vaginosis and is a generic version of Bausch Health US LLC’s MetroGel-Vaginal.
January 19, 2022
A phase 2, multicenter study has found relugolix (Myfembree; Myovant Sciences) significantly decreases menstrual blood loss in women with uterine leiomyomas and is mostly well tolerated. Relugolix is a small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist.
January 13, 2022
Maneesh Jain, CEO and co-founder of Mirvie, a proprietary RNA platform that uses blood samples to predict pregnancy complications such as preeclampsia, sits down with Contemporary OB/GYN to discuss the potential of the test.